Skip navigation
Watchlist Sponsored By :

Current DateTime: 03:19:52 10 Jul 2009
LinksList Documentid: 24355697
  • Highest Grossing Movies

      What are the highest grossing movies of all time, adjusted for inflation? Click ahead to find out!

  • Most Expensive Places To Live

      Each year, Mercer Consulting assembles its ranking of the most expensive places to live. Mercer compiles information from 143 cities worldwide.

  • Recession-Resistant US Cities

      Some cities have been hit much harder than others during the recession. Here are the metro areas faring the best.


Current DateTime: 03:19:52 10 Jul 2009
LinksList Documentid: 24890560
  • Boom, Bust and Blame

      The inside story of the economic crisis that has gripped the entire world.

  • E3: Gaming's Cutting Edge

      North America's premier computer and video game trade show draws tens of thousands of professionals to experience the future of interactive entertainment.

  • The Fall of GM

      A look into the fall of General Motors as the automaker heads toward bankruptcy and an effective nationalization.

By: Peter Kang | 04 Jun 2007 | 04:27 PM ET
Text Size

Onyx Pharmaceuticals [ONXX  Loading...      ()   ] was the big winner at the annual meeting of the American Society of Clinical Oncology, or ASCO, held in Chicago. Onyx shares rose more than 8% on Monday after the company announced positive results for cancer drug Nexavar.

The Emeryville, Calif.-based company and marketing partner Bayer said liver cancer patients taking Nexavar extended survival rates by about three months compared to those taking a placebo, according to data from a recent clinical trial. The drug is already approved for the treatment of kidney cancer.

Bear Stearns upgraded the Onyx shares to "outperform" from "peer perform" and raised the price target to $40. Analyst Akhtar Samad said in a note sent to clients that results of the trial made him more confident Nexavar will become the "standard of care" in hepatocellular carcinoma, a form of liver cancer and fifth most common type of cancer overall.

Biotech giant Genentech [DNA  Loading...      ()   ] reported new data for cancer drug Avastin below expectations, sending shares down 1.95%. Avastin failed to show an overall survival benefit in colon cancer patients taking the drug along with the most commonly used chemotherapy, according to a clinical trial known as AVAiL. "Data from the AVAiL trial were disappointing in terms of Avastin's activity, and will likely drive physicians to the lower dose of the drug over time," said Bret Holley, an analyst with CIBC World Markets.

Pfizer [PFE  Loading...      ()   ] reported promising resutls for experimental pancreatic cancer treatment axitinib. The world's largest drugmaker said data from an early Phase II trial was strong enough to warrant further studies.

Celgene [CELG  Loading...      ()   ] shares fell slightly after the biotech firm announced new data for Revlimid in first-line multiple myeloma in line with expectations. Celgene said 96% of patients taking Revlimid and low dose dexamethasone, a steroid, survived for one year, a greater percentage than any other previous first-line trial.

Shares of both SuperGen [SUPG  Loading...      ()   ] and MGI Pharma [MOGN  Loading...      ()   ] rose following lukewarm data for rival treatments of Dacogen, the companies' drug for myelodysplastic syndrome, or MDS. Data for competitive products Pharmion's Vidaza and Celgene's Revlimid appeared inferior to Dacogen, said Vinny Jindal, an analyst with ThinkEquity Partners. "We believe Dacogen will emerge as the front-line standard of care for higher-risk MDS patients, with Vidaza or Vidaza plus Revlimid used in Dacogen-failures," he wrote in a client note.

Shares of ImClone Systems [IMCL  Loading...      ()   ] fell 2.4% after the company announced mixed results for cancer drug Erbitux. The company said the drug combined with chemotherapy delayed death in patients with head-and-neck cancer by three months. "We think this is a major impact," Dr. Eric Rowinsky, ImClone's chief medical officer, told CNBC's Mike Huckman.

In addition, Erbitux, co-marketed and co-developed with Bristol-Myers Squibb [BMY  Loading...      ()   ], delayed progression of the colon cancer by one month when added to standard chemotherapy treatments, according to new data released Monday.

IDM Pharma [IDMI  Loading...      ()   ] was another winner, rising more than 16% on Monday after the tiny drug developer said data from a Phase II trial of experimental vaccine EP-2101 was shown to be well tolerated in lung cancer patients. The company said one-year survival in patients treated with the vaccine was 60% compared with 49% of patients in the control group.

ArQule [ARQL  Loading...      ()   ] released results of experimental drug ARQ 197, which showed good safety, promising activity and potential for reducing tumors. But investors appeared to be disappointed with the results, sending shares down sharply on Monday.

Shares of Telik [TELK  Loading...      ()   ] fell 22% after the company reported disappointing data for experimental lung cancer drug telcyta. A late-stage study of the drug in patients with advanced non-small cell lung cancer failed to show superiority compared with AstraZeneca's Iressa.

ASCO Winners and Losers
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...

Peter Kang is a markets writer with CNBC.com and can be reached at .

© 2009 CNBC.com
Tools:
Print EmailAdd This share icon


Current DateTime: 02:07:26 10 Jul 2009
LinksList Documentid: 29778428

Current DateTime: 01:04:04 10 Jul 2009
LinksList Documentid: 29779196

Current DateTime: 02:18:56 10 Jul 2009
LinksList Documentid: 29779199

Current DateTime: 01:05:45 10 Jul 2009
LinksList Documentid: 29779198
CNBCCNBC
About CNBC  |  Site Map  |  Privacy Policy  |  Terms of Service  |  Video Reprints  |  Advertise  |  Help  |  Contact
Partners: AOL Money  |  BloggingStocks.com
CNBC is a Division of NBC Universal
  Data is a real-time snapshot *Data is delayed at least 15 minutes
Global Business and Financial News, Stock Quotes, and Market Data and Analysis

© 2009 CNBC, Inc.  All Rights Reserved.
Thomson ReutersThomson Reuters